Cell therapy using human induced pluripotent stem cell-derived renal progenitors ameliorates acute kidney injury in mice

Takafumi Toyohara, Shin Ichi Mae, Shin Ichi Sueta, Tatsuyuki Inoue, Yukiko Yamagishi, Tatsuya Kawamoto, Tomoko Kasahara, Azusa Hoshina, Taro Toyoda, Hiromi Tanaka, Toshikazu Araoka, Aiko Sato-Otsubo, Kazutoshi Takahashi, Yasunori Sato, Noboru Yamaji, Seishi Ogawa, Shinya Yamanaka, Kenji Osafune

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Acute kidney injury (AKI) is defined as a rapid loss of renal function resulting from various etiologies, with a mortality rate exceeding 60% among intensive care patients. Because conventional treatments have failed to alleviate this condition, the development of regenerative therapies using human induced pluripotent stem cells (hiPSCs) presents a promising new therapeutic option for AKI. We describe our methodology for generating renal progenitors from hiPSCs that show potential in ameliorating AKI.Weestablished a multistep differentiation protocol for inducing hiPSCs into OSR1 + SIX2 + renal progenitors capable of reconstituting three-dimensional proximal renal tubule-like structures in vitro and in vivo. Moreover, we found that renal subcapsular transplantation of hiPSC-derived renal progenitors ameliorated the AKI in mice induced by ischemia/reperfusion injury, significantly suppressing the elevation of blood urea nitrogen and serum creatinine levels and attenuating histopathological changes, such as tubular necrosis, tubule dilatation with casts, and interstitial fibrosis. To our knowledge, few reports demonstrating the therapeutic efficacy of cell therapy with renal lineage cells generated from hiPSCs have been published. Our results suggest that regenerative medicine strategies for kidney diseases could be developed using hiPSC-derived renal cells.

Original languageEnglish
Pages (from-to)980-992
Number of pages13
JournalStem Cells Translational Medicine
Volume4
Issue number9
DOIs
Publication statusPublished - 2015 Sep 1
Externally publishedYes

Fingerprint

Induced Pluripotent Stem Cells
Cell- and Tissue-Based Therapy
Acute Kidney Injury
Kidney
Proximal Kidney Tubule
Regenerative Medicine
Blood Urea Nitrogen
Kidney Diseases
Therapeutics
Critical Care
Reperfusion Injury
Kidney Transplantation
Dilatation
Creatinine
Fibrosis
Necrosis
Mortality
Serum

Keywords

  • Acute kidney injury
  • Cell- and tissue-based therapy
  • Induced pluripotent stem cells
  • Kidney
  • Nephrons
  • Renal progenitors
  • SIX2 protein

ASJC Scopus subject areas

  • Developmental Biology
  • Cell Biology

Cite this

Cell therapy using human induced pluripotent stem cell-derived renal progenitors ameliorates acute kidney injury in mice. / Toyohara, Takafumi; Mae, Shin Ichi; Sueta, Shin Ichi; Inoue, Tatsuyuki; Yamagishi, Yukiko; Kawamoto, Tatsuya; Kasahara, Tomoko; Hoshina, Azusa; Toyoda, Taro; Tanaka, Hiromi; Araoka, Toshikazu; Sato-Otsubo, Aiko; Takahashi, Kazutoshi; Sato, Yasunori; Yamaji, Noboru; Ogawa, Seishi; Yamanaka, Shinya; Osafune, Kenji.

In: Stem Cells Translational Medicine, Vol. 4, No. 9, 01.09.2015, p. 980-992.

Research output: Contribution to journalArticle

Toyohara, T, Mae, SI, Sueta, SI, Inoue, T, Yamagishi, Y, Kawamoto, T, Kasahara, T, Hoshina, A, Toyoda, T, Tanaka, H, Araoka, T, Sato-Otsubo, A, Takahashi, K, Sato, Y, Yamaji, N, Ogawa, S, Yamanaka, S & Osafune, K 2015, 'Cell therapy using human induced pluripotent stem cell-derived renal progenitors ameliorates acute kidney injury in mice', Stem Cells Translational Medicine, vol. 4, no. 9, pp. 980-992. https://doi.org/10.5966/sctm.2014-0219
Toyohara, Takafumi ; Mae, Shin Ichi ; Sueta, Shin Ichi ; Inoue, Tatsuyuki ; Yamagishi, Yukiko ; Kawamoto, Tatsuya ; Kasahara, Tomoko ; Hoshina, Azusa ; Toyoda, Taro ; Tanaka, Hiromi ; Araoka, Toshikazu ; Sato-Otsubo, Aiko ; Takahashi, Kazutoshi ; Sato, Yasunori ; Yamaji, Noboru ; Ogawa, Seishi ; Yamanaka, Shinya ; Osafune, Kenji. / Cell therapy using human induced pluripotent stem cell-derived renal progenitors ameliorates acute kidney injury in mice. In: Stem Cells Translational Medicine. 2015 ; Vol. 4, No. 9. pp. 980-992.
@article{24652baee804437b8c09ee3a5058fbf9,
title = "Cell therapy using human induced pluripotent stem cell-derived renal progenitors ameliorates acute kidney injury in mice",
abstract = "Acute kidney injury (AKI) is defined as a rapid loss of renal function resulting from various etiologies, with a mortality rate exceeding 60{\%} among intensive care patients. Because conventional treatments have failed to alleviate this condition, the development of regenerative therapies using human induced pluripotent stem cells (hiPSCs) presents a promising new therapeutic option for AKI. We describe our methodology for generating renal progenitors from hiPSCs that show potential in ameliorating AKI.Weestablished a multistep differentiation protocol for inducing hiPSCs into OSR1 + SIX2 + renal progenitors capable of reconstituting three-dimensional proximal renal tubule-like structures in vitro and in vivo. Moreover, we found that renal subcapsular transplantation of hiPSC-derived renal progenitors ameliorated the AKI in mice induced by ischemia/reperfusion injury, significantly suppressing the elevation of blood urea nitrogen and serum creatinine levels and attenuating histopathological changes, such as tubular necrosis, tubule dilatation with casts, and interstitial fibrosis. To our knowledge, few reports demonstrating the therapeutic efficacy of cell therapy with renal lineage cells generated from hiPSCs have been published. Our results suggest that regenerative medicine strategies for kidney diseases could be developed using hiPSC-derived renal cells.",
keywords = "Acute kidney injury, Cell- and tissue-based therapy, Induced pluripotent stem cells, Kidney, Nephrons, Renal progenitors, SIX2 protein",
author = "Takafumi Toyohara and Mae, {Shin Ichi} and Sueta, {Shin Ichi} and Tatsuyuki Inoue and Yukiko Yamagishi and Tatsuya Kawamoto and Tomoko Kasahara and Azusa Hoshina and Taro Toyoda and Hiromi Tanaka and Toshikazu Araoka and Aiko Sato-Otsubo and Kazutoshi Takahashi and Yasunori Sato and Noboru Yamaji and Seishi Ogawa and Shinya Yamanaka and Kenji Osafune",
year = "2015",
month = "9",
day = "1",
doi = "10.5966/sctm.2014-0219",
language = "English",
volume = "4",
pages = "980--992",
journal = "Stem cells translational medicine",
issn = "2157-6564",
publisher = "AlphaMed Press",
number = "9",

}

TY - JOUR

T1 - Cell therapy using human induced pluripotent stem cell-derived renal progenitors ameliorates acute kidney injury in mice

AU - Toyohara, Takafumi

AU - Mae, Shin Ichi

AU - Sueta, Shin Ichi

AU - Inoue, Tatsuyuki

AU - Yamagishi, Yukiko

AU - Kawamoto, Tatsuya

AU - Kasahara, Tomoko

AU - Hoshina, Azusa

AU - Toyoda, Taro

AU - Tanaka, Hiromi

AU - Araoka, Toshikazu

AU - Sato-Otsubo, Aiko

AU - Takahashi, Kazutoshi

AU - Sato, Yasunori

AU - Yamaji, Noboru

AU - Ogawa, Seishi

AU - Yamanaka, Shinya

AU - Osafune, Kenji

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Acute kidney injury (AKI) is defined as a rapid loss of renal function resulting from various etiologies, with a mortality rate exceeding 60% among intensive care patients. Because conventional treatments have failed to alleviate this condition, the development of regenerative therapies using human induced pluripotent stem cells (hiPSCs) presents a promising new therapeutic option for AKI. We describe our methodology for generating renal progenitors from hiPSCs that show potential in ameliorating AKI.Weestablished a multistep differentiation protocol for inducing hiPSCs into OSR1 + SIX2 + renal progenitors capable of reconstituting three-dimensional proximal renal tubule-like structures in vitro and in vivo. Moreover, we found that renal subcapsular transplantation of hiPSC-derived renal progenitors ameliorated the AKI in mice induced by ischemia/reperfusion injury, significantly suppressing the elevation of blood urea nitrogen and serum creatinine levels and attenuating histopathological changes, such as tubular necrosis, tubule dilatation with casts, and interstitial fibrosis. To our knowledge, few reports demonstrating the therapeutic efficacy of cell therapy with renal lineage cells generated from hiPSCs have been published. Our results suggest that regenerative medicine strategies for kidney diseases could be developed using hiPSC-derived renal cells.

AB - Acute kidney injury (AKI) is defined as a rapid loss of renal function resulting from various etiologies, with a mortality rate exceeding 60% among intensive care patients. Because conventional treatments have failed to alleviate this condition, the development of regenerative therapies using human induced pluripotent stem cells (hiPSCs) presents a promising new therapeutic option for AKI. We describe our methodology for generating renal progenitors from hiPSCs that show potential in ameliorating AKI.Weestablished a multistep differentiation protocol for inducing hiPSCs into OSR1 + SIX2 + renal progenitors capable of reconstituting three-dimensional proximal renal tubule-like structures in vitro and in vivo. Moreover, we found that renal subcapsular transplantation of hiPSC-derived renal progenitors ameliorated the AKI in mice induced by ischemia/reperfusion injury, significantly suppressing the elevation of blood urea nitrogen and serum creatinine levels and attenuating histopathological changes, such as tubular necrosis, tubule dilatation with casts, and interstitial fibrosis. To our knowledge, few reports demonstrating the therapeutic efficacy of cell therapy with renal lineage cells generated from hiPSCs have been published. Our results suggest that regenerative medicine strategies for kidney diseases could be developed using hiPSC-derived renal cells.

KW - Acute kidney injury

KW - Cell- and tissue-based therapy

KW - Induced pluripotent stem cells

KW - Kidney

KW - Nephrons

KW - Renal progenitors

KW - SIX2 protein

UR - http://www.scopus.com/inward/record.url?scp=84940042150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940042150&partnerID=8YFLogxK

U2 - 10.5966/sctm.2014-0219

DO - 10.5966/sctm.2014-0219

M3 - Article

VL - 4

SP - 980

EP - 992

JO - Stem cells translational medicine

JF - Stem cells translational medicine

SN - 2157-6564

IS - 9

ER -